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Introduction
Advances in the management of congenital heart disease 
(CHD) have led to most patients reaching child-bearing age, 
with an increasing number of such women becoming pregnant.
[1] The physiological changes that occur during pregnancy, 
including increases in blood volume, heart rate and cardiac 
output, represent an added cardiovascular burden which may 
be poorly tolerated by women with CHD, especially those with 
haemodynamically significant residua.[2] Such pregnancies are 
also at higher risk of neonatal complications.[3,4]  Three main 
tools have been proposed for risk stratification of maternal 
cardiovascular complications among women with heart 
disease.[5]  The CARPREG score [4] and modified World Health 
Organisation (WHO) classification [6,7] can be applied to women 
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with both CHD and acquired heart disease (AHD), while the 
ZAHARA score [8] is designed specifically for women with CHD. 
CARPREG and ZAHARA scores consider the maternal clinical 
cardiac status to calculate risk of cardiovascular complications. 
In the modified WHO classification, pregnancies are classified 
into four risk groups based on specific heart lesions, with 
maternal risk ranging from very low in WHO class I to extremely 
high and warranting advice against pregnancy in class IV.[6,7]
Malta has a population of around 425,000 and the main religion 
is Roman Catholic.[9]  Termination of pregnancy is illegal up 
to the time of writing of this manuscript.  Malta’s health care 
system is funded through taxation and national insurance, and 
specialised services, including a dedicated service for grown-
ups with congenital heart disease (GUCH) are provided in one 
main teaching hospital.  Obstetric data covering all deliveries to 
residents and non-residents taking place on the Maltese islands is 
collected and administered by the National Obstetric Information 
System (NOIS), which was launched by the Department of Health 
Information and Research in 1999.[10] There has been a trend of 
increasing maternal age over the past decade, with the 30-34 
years’ age bracket being the one with most reported deliveries 
(36.3%) in 2015.  There were 3544 reported deliveries in women 
of Maltese nationality in 2015, 92.7% of all babies were born at 
term and the average birth weight was 3217g.  Two maternal 
deaths were reported in the last decade.[10]
The overall incidence of CHD in Malta has been reported at 
around 0.8%, which is similar to that in other European countries.
[11]  Virtually all congenital cardiac surgery on children and adults 
born in Malta is carried out in overseas tertiary referral centres, 
in the United Kingdom, through a reciprocal National Health 
Service agreement.  A number of structural cardiac interventions 
are carried out locally by visiting specialists.  A GUCH service 
was initiated in the late 1990s and expanded considerably over 
the last decade.  It includes a specific service for the provision 
of preconceptual counselling to female patients who want to get 
pregnant and for their management during pregnancy through 
close collaboration with obstetricians and anaesthetists.
The aims of this retrospective study were (a) to describe maternal 
outcomes among women with CHD in Malta and (b) to investigate 
the potential impact of maternal CHD on obstetric and offspring 
outcomes through comparison with reported outcomes in age-
matched women with no history of cardiovascular disease in the 
general Maltese population. 
Methods
All known pregnancies in women of Maltese nationality with 
CHD for the 8-year period 2007 – 2014 were retrieved from our 
institutional database (“GUCH pregnancy cohort”).  Baseline 
characteristics, cardiac events and obstetric and offspring 
outcomes for these women were obtained retrospectively 
from hospital paper notes and digital investigation reports.  An 
individual twenty-fold random matching based on subject age 
was performed out of all 29,349 pregnancies in Maltese women 
with no documented cardiovascular disease as collected by 
NOIS for the same study period.  This generated the age-matched 
control cohort of 540 pregnancies referred to in the manuscript 
as “non-CVD pregnancy cohort”.  NOIS pregnancy entries for 
women of non-Maltese nationality were excluded primarily to 
avoid any bias related to potentially differing epidemiological 
and/or genetic characteristics, as well as due to the possibility 
of their medical data leading up to the index pregnancy being 
incomplete. Maltese pregnancies with incomplete obstetric 
and/or offspring outcome data were also excluded during the 
matching process.  
The term “tachyarrhythmias” refers to any symptomatic 
sustained and non-sustained tachyarrhythmia and excludes 
incidental asymptomatic atrial/ventricular ectopy.  Ventricular 
and valvular function was based on echocardiographic findings 
and follows international guidelines.[12]  Left ventricular systolic 
dysfunction is defined as an ejection fraction <55% and right 
ventricular systolic dysfunction is defined as a tricuspid annular 
plane systolic excursion (TAPSE) <16mm and fractional area 
change <35%.  Aortic outflow tract obstruction is referred to as 
moderate if peak velocity is 3.0-3.9m/s and mean pressure drop 
is 25-40mmHg and severe if peak velocity is ³4.0m/s and mean 
pressure drop is >40mmHg.  Pulmonary outflow tract obstruction 
is defined as moderate if peak velocity is 3.0-4.0m/s and severe 
if >4.0m/s.  Mitral regurgitation is defined as more than mild if 
proximal isovelocity surface area (PISA) is >0.4cm and vena 
contracta >0.3cm.  Aortic regurgitation is defined as more 
than mild if pressure half time is <500ms and vena contracta 
is >0.3cm.  Pulmonary regurgitation is referred to as severe if 
pressure half-time is <100ms and colour flow Doppler origin of 
the regurgitant jet is from the bifurcation of the branch pulmonary 
arteries.  Severity of tricuspid regurgitation is based mostly on 
visual assessment.
The outcomes compared between the subjects in the two study 
cohorts were based on those collected by NOIS.  Obstetric 
outcomes studied were threatened abortion, threatened 
premature labour, antepartum haemorrhage, placenta praevia, 
placental abruption, suspected intrauterine growth retardation 
(IUGR), maternal infections, hypertensive diseases of pregnancy, 
gestational diabetes, need for hysterectomy within 24 hours 
of delivery, retained placenta, severe haemorrhage (defined 
as blood loss of 1 litre in 2 hours), need for blood transfusion, 
dystocia and maternal death.  Offspring outcomes studied were 
number of offspring per pregnancy, offspring gender, pregnancy 
duration, prematurity (pregnancy duration < 37 weeks), small-
for-gestational age (SGA) births (birth weight <10th centile 
for gestational age), birth weight, presence of congenital 
malformations diagnosed at birth and occurrence of stillbirths 
and neonatal death.  Informed consent was obtained from all 
participants.  The study protocol was approved by the University 
of Malta Research Ethics Committee and conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki.
Statistical methods
Categorical variables were analysed using Chi-squared tests. 
Fisher’s Exact test was applied in the case of smaller sample 
sizes.  Shapiro-Wilk test applied to numerical variables (pregnancy 
duration and birth weight) showed a non-normal distribution. 
Subsequently, Mann-Whitney U test was used for comparison of 
these variables between the two study cohorts.  Analyses were 
performed using SPSS 21 (IBM® SPSS® 21, SPSS Inc., Chicago 
IL, USA).  All statistical analyses were two-sided and statistical 
significance was defined as p≤0.05.
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Results
The GUCH pregnancy cohort consisted of 27 pregnancies in 
24 women, with 9 pregnancies belonging to modified WHO 
class I, 15 pregnancies to modified WHO class II/II-III and 3 
pregnancies to modified WHO class III (Table 1).  Maternal 
baseline characteristics are summarised in Table 2.  Repaired 
tetralogy of Fallot was the commonest congenital heart lesion, 
featuring in 6/27 (22.2%) GUCH pregnancies.  Mean maternal 
age was 27.44 ± 5.24 years (range 15–41 years).  All women 
were in New York Heart Association (NYHA) class I prior to the 
index pregnancy and none had cyanosis at baseline.  Three 
patients were on cardiac medications prior to pregnancy: two 
women were on aspirin and one patient was on warfarin.  Only 
one patient – a case of atriopulmonary (AP) Fontan surgery for 
tricuspid atresia – had a history of prior arrhythmias in the form 
of sustained atrial flutter needing direct current cardioversion in 
the past.  Complete echocardiographic data was available for 
23/27 GUCH pregnancies.  In all these cases, there was good 
systemic ventricular function at baseline.  One patient had 
moderate congenital aortic stenosis (AS) and another patient had 
moderate right ventricular outflow tract obstruction (RVOTO) at 
branch pulmonary artery level but no patients had severe outflow 
tract obstruction.
Cardiac events and cardiac medication use in pregnancy in the 
GUCH cohort is summarised in Table 3.  Cardiac events were 
uncommon with only one patient, with a history of tricuspid atresia 
and atriopulmonary (AP) Fontan surgery, developing paroxysmal 
atrial arrhythmias and heart failure.  The same patient was also 
the only one to require antiarrhythmic therapy, low-dose diuretics 
and anticoagulation during pregnancy.  Two other women, one 
with total cavopulmonary connection (TCPC) and one with recent 
percutaneous closure of an atrial septal defect (ASD) remained 
on low-dose aspirin during pregnancy. 
Tables 4 and 5 summarise the results of comparison of obstetric 
and offspring outcomes respectively.  There were no significant 
differences in the frequency of pregnancy and delivery-related 
complications between the two cohorts.  Unassisted vaginal 
delivery was the commonest mode of delivery in both cohorts, 
however it was less common among subjects in the GUCH 
cohort (GUCH 51.9% vs. non-CVD 64.6%).  Conversely, 
elective pre-labour Caesarean section was employed more 
frequently among women in the GUCH cohort (8/27; 29.6%) 
when compared to those in the non-CVD cohort (83/540; 
15.4%).  Four of the 8 Caesarean sections (50%) in the GUCH 
pregnancy cohort were performed for cardiac indications, 3/8 
(37.5%) had obstetric indications and one was performed based 
on patient preference.  Instrumental delivery was used for 2/27 
(5.4%) GUCH pregnancies and for 20/540 (3.7%) non-CVD 
pregnancies.  The differences in delivery methods between the 
two cohorts were statistically significant (p=0.02). There were 
more premature births in the GUCH cohort (11.1% vs. 4.1%) 
though this difference did not reach statistical significance 
(p=0.11).  Overall pregnancy duration in the two cohorts was 
not significantly different (median duration GUCH 38 weeks vs. 
non-CVD 39 weeks; p=0.14).  Women in the GUCH cohort gave 
birth to significantly smaller babies (median birth weight: GUCH 
3030g vs. non-CVD 3230g; p=0.045) and showed a trend 
towards having more SGA babies (GUCH 18.5% vs. non-CVD 
8.4%; p=0.08).  There was also a trend towards more frequent 
congenital malformations among offspring born to GUCH 
women (7.4% vs. 2.4%; p=0.06).
Discussion
Maternal CHD is traditionally associated with poorer pregnancy 
outcomes, mainly through increased risk of cardiac events 
in the mother and complications in the foetus.[6]  Neonatal 
complication rates of 20-28% and neonatal mortality of 1-4% 
have been reported among women with all forms of heart 
disease.[3,4,8,13,14]  The commonest reported complications 
are premature births, small-for-gestational-age birthweights 
and respiratory distress syndrome.  The maternal predictors 
of neonatal events are baseline NYHA class >II or cyanosis, 
maternal left heart obstruction, smoking during pregnancy, 
multiple gestation, use of oral anticoagulation during 
pregnancy and the presence of a mechanical valve prosthesis.
[6] Hypertensive diseases of pregnancy and postpartum 
haemorrhage (PPH) are the commonest obstetric complications 
reported in women with heart disease.[3,13]  Contrary to 
maternal and neonatal complications, the reported experience 
with obstetric complications is more variable.  Whereas the 
CARPREG investigators found coarctation of the aorta as an 
independent predictor for pregnancy-induced hypertension and 
use of antiocoagulants in the peripartum period and cyanosis as 
independent predictors for PPH [4], the ZAHARA investigators 
found no such associations in their cohort.[8] 
Adverse maternal cardiac events were only observed in one of 
the 27 GUCH pregnancies (3.7%) in our cohort, with the same 
patient developing symptomatic paroxysmal atrial arrhythmia as 
well as heart failure.  This pregnancy was the one with the highest 
predicted risk in our cohort (CARPREG risk = 27%; ZAHARA risk 
= 70%; modified WHO class III).  Arrhythmias and heart failure 
have been consistently reported as the commonest maternal 
cardiovascular complications.[3,4,8,15]  Our cardiac event rate of 
3.7% is lower than what has been reported in most large studies 
concentrating on pregnancy in women with CHD, where cardiac 
event rates ranged from 4% to 25%.[1,3,5,8,13,16,17] Although 
this finding is reassuring, it should be interpreted with caution as 
it is likely to be, at least partly, due to fewer women with more 
complex forms of CHD and poorer baseline cardiac status in the 
Maltese GUCH cohort when compared to other studies referred 
to earlier.  In fact, both CARPREG and ZAHARA risk scores for 
the 23/27 patients in the Maltese GUCH cohort with complete 
pre-pregnancy echocardiographic data were low, with an overall 
CARPREG mean risk of 6.91 ± 6.34% (median 5%) and an 
overall ZAHARA mean risk of 8.25 ± 13.89% (median 2.9%). 
Similarly, only three pregnancies occurred in women considered 
to be at high risk of maternal cardiac complications by modified 
WHO classification, with all other pregnancies being in lower risk 
categories (Table 1).
The commonest primary cardiac lesion in our series was tetralogy 
of Fallot (TOF) (6/27 in 6 patients; 22.2% pregnancies), followed by 
coarctation of the aorta (4/27 in 3 patients; 14.8% pregnancies). 
No maternal cardiac events were reported in either of these 
groups.  RV dysfunction and/or moderate to severe PR have 
been reported as the main risk factors for cardiac complications 
in pregnancies in women with TOF.[6,18-20] All our TOF patients 
had undergone complete repair in infancy or early childhood. 
Although two women had moderate pulmonary regurgitation 
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(PR) and one had severe PR, all 6 patients were asymptomatic 
and all had normal right ventricular (RV) function at baseline.  All 
three coarctation patients in our cohort had undergone surgical 
repair, and none had significant residua or hypertension prior 
to pregnancy.  Consequently, they were all at low risk of aortic 
rupture and cerebral aneurysm rupture, which are the maternal 
complications mostly reported in this patient group.[6] 
Three women went through a high-risk pregnancy: one patient 
with atrial switch (Mustard repair) for transposition of the great 
arteries (TGA) and two patients with Fontan-type palliation. 
Our only atrial switch patient had good systemic RV function, 
no significant TR and no previous arrhythmias, putting her in a 
more advantageous position for a good maternal outcome.[6,21-
23] Both women with Fontan palliation had good NYHA status, 
retained ventricular function and no significant atrioventricular 
valve regurgitation at baseline, all factors considered favourable 
with this type of circulation.[6] However, a previous history of 
atrial arrhythmias requiring treatment and a possibly less efficient 
type of Fontan circuit (classical Fontan with right atrium to 
pulmonary artery conduit) in the patient with AP Fontan resulted 
in a difference in occurrence of cardiac events between the 
pregnancies.[24]  Thus, even when assessed by cardiac lesion, 
most of our patients tolerated pregnancy without maternal 
complications, largely because their anatomy and function at 
baseline put them at the more favourable end of the spectrum.
Our study is one of few in the literature to compare pregnancy 
outcomes in GUCH patients with those in contemporary women 
without heart disease from the same population.[1,14,17,25] 
There were significantly more deliveries by Caesarean section 
and fewer normal vaginal deliveries in our GUCH cohort, which 
compares to the reported literature.[1,14,17,25]  There was 
no excess of obstetric complications in our GUCH pregnancy 
cohort when compared to non-CVD women (Table 4).  These 
findings are similar to those reported in the Canadian study 
by Siu et al [14], the German study by Hrycyk et al [25] and 
those stemming from the Registry Of Pregnancy And Cardiac 
disease (ROPAC).[17] Conversely, in their nationwide U.S. study 
from 2015, Thompson et al found the odds of several obstetric 
complications, including gestational diabetes, preterm labour, 
placental abruption and postpartum haemorrhage, to be 
significantly higher among delivery hospitalisations for women 
with CHD.[1] 
Overall, neonatal outcomes in our GUCH cohort were good 
and, in the main, not significantly worse than those in the non-
CVD cohort.  Although there was a higher rate of premature 
Table 1. 
Modified WHO class I (n=9)
Repaired ASD 3 (11.1%) Repaired PDA 3 (11.1%)
Repaired PS 1 (3.7%) Repaired TAPVD 1 (3.7%)
Repaired pAVSD 1 (3.7%)
Modified WHO class II / II-III (n=15)
Repaired CoA 4 (14.8%) Unoperated VSD 1 (3.7%)
Repaired TOF 6 (22.2%) SAS 3 (11.1%)
Congenital AS 1 (3.7%)
Modified WHO class III (n=3)
Fontan-type 
palliation 2 (7.4%) TGA-Mustard 1 (3.7%)
Congenital heart lesions in the 27 GUCH pregnancies divided by 
modified WHO classification of maternal cardiovascular risk [6,7].
Abbreviations: 
ASD = atrial septal defect; 
VSD = ventricular septal defect; 
PDA = patent ductus arteriosus; 
CoA = coarctation of the aorta; 
TOF = tetralogy of Fallot; 
PS = pulmonary stenosis; 
TAPVD = total anomalous pulmonary venous drainage; 
SAS = subaortic stenosis; 
TGA = transposition of great arteries; AS = aortic stenosis; 
pAVSD = partial atrioventricular septal defect; WHO = World 
Health Organisation
Table 2. 
Number of 
pregnancies (%)
(a) Clinical characteristics (N = 27)
Cyanosis 0 (0)
NYHA functional class I 27 (100)
History of atrial arrhythmias 1 (3.7)
History of ventricular arrhythmias 0 (0)
Permanent pacemaker / ICD in situ 0 (0)
History of congestive heart failure 0 (0)
(b) Cardiac medications (N = 27)
Antiplatelets 2 (7.4)
Oral anticoagulant 1 (3.7)
Antiarrhythmics 0 (0)
Antihypertensive agent 0 (0)
Diuretics 0 (0)
(c) Echocardiographic parameters (N = 23)*
Systemic ventricular dysfunction 0 (0)
Subpulmonary ventricular dysfunction 0 (0)
Moderate aortic outflow tract obstruction 1 (4.3)
Severe aortic outflow tract obstruction 0 (0)
Moderate pulmonary outflow tract obstruction 1 (4.3)
Severe pulmonary outflow tract obstruction 0 (0)
More than mild mitral regurgitation 0 (0)
More than mild aortic regurgitation 0 (0)
More than mild tricuspid regurgitation 0 (0)
More than mild pulmonary regurgitation 3 (13)
Maternal baseline cardiac characteristics for the 27 pregnancies in 
the GUCH cohort.
* Complete echocardiographic data was available for 23/27 
pregnancies.
Abbreviations: 
ICD = implantable cardioverter-defibrillator; 
NYHA = New York Heart Association
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births in our GUCH cohort (11.1% vs. 4.1%), this difference 
did not reach statistical significance (p=0.11).  Furthermore, 
the lowest pregnancy duration observed was only 36 weeks 
and there were no cases of severe prematurity.  This contrasts 
with the observations made by other studies where higher rates 
of premature births in GUCH pregnancies [4,26], as well as 
significantly more premature births when compared to women 
without heart disease, were reported.[14,17]  However, it should 
be noted that some of these studies included other forms of 
heart disease apart from CHD and had a higher proportion of 
women with a less favourable baseline maternal status and thus 
a higher propensity for poorer neonatal outcomes.
The main difference in offspring outcomes observed between 
patient and control cohorts related to significantly smaller babies 
born to women with CHD (median birth weight GUCH 3030g vs. 
non-CVD 3230g; p=0.045).  There was also a trend towards more 
babies being small-for-gestational age in the GUCH cohort (18.5% 
vs. 8.4%; p=0.08).  This observation has been documented by 
several other studies.[17,25,27]  Maternal cyanosis and poor 
cardiac output are recognized as the main risk factors for foetal 
growth restriction and lower birth weights.[27] The fact that, on 
the whole, our GUCH cohort consisted of women with good 
saturations and satisfactory cardiac output at baseline, and that 
use of medications linked with IUGR was minimal, suggests 
that there might be other less well-recognized factors coming 
into play to interfere with foetal growth in mothers with CHD.  It 
could also be argued that the “cardiologist’s definition” of good 
cardiac output based on imaging and functional status might not 
necessarily translate into equally good uteroplacental flow.
Table 3. 
Number of  
pregnancies (%)
Cardiac events 1 (3.7)
Heart failure 1 (3.7)+
Atrial arrhythmias requiring treatment 1 (3.7) +
Ventricular arrhythmias requiring treatment 0 (0)
Thromboembolic events 0 (0)
Infective endocarditis 0 (0)
Need for urgent percutaneous / surgical 
intervention 0 (0)
Cardiac medications used during pregnancy
Antiplatelets 2 (7.4)
Low-molecular weight heparin 1 (3.7)*
Antiarrhythmic agent/s 1 (3.7)*
Diuretic 1 (3.7)*
Antihypertensive agent 0 (0)
Cardiac events and need for cardiac medication use during 
pregnancy in the 27-patient GUCH pregnancy cohort
+* The only patient to develop significant cardiac events during 
pregnancy and to require anticoagulation, antiarrhythmic therapy 
and a diuretic was a patient with atriopulmonary Fontan for tricuspid 
atresia.  
Table 4.
Complication GUCH pregnancies
Non-CVD 
pregnancies
p 
value
Threatened abortion 1/27 (3.7%) 28/540 (5.2%) 1.00
Threatened premature 
labour 0/27 (0%) 13/539 (2.4%) 1.00
Antepartum 
haemorrhage 0/27 (0.0%) 9/540 (1.7%) 1.00
Placenta praevia 0/27 (0.0%) 2/539 (0.4%) 1.00
Placental abruption 0/27 (0.0%) 3/540 (0.6%) 1.00
Suspected IUGR 2/27 (7.4%) 28/539 (5.2%) 0.65
Infections 0/27 (0%) 32/540 (5.9%) 0.39
Gestational 
hypertension 0/27 (0.0%) 37/540 (6.9%) 0.24
Pre-eclampsia/
eclampsia 0/27 (0.0%) 3/540 (0.6%) 1.00
Gestational diabetes 0/27 (0%) 25/539 (4.6%) 0.62
Hysterectomy within 
24hrs 0/27 (0%) 0/540 (0%) /
Retained placenta 0/27 (0%) 3/540 (0.6%) 1.00
Haemorrhage  
(1l in 2hrs) 0/27 (0%) 0/540 (0%) /
Blood transfusion 0/27 (0%) 2/539 (0.4%) 1.00
Dystocia 0/27 (0%) 1/540 (0.2%) 1.00
Maternal death 0/27 (0%) 0/540 (0%) /
Comparison of obstetric complications between GUCH and non-
CVD cohorts
Abbreviations: 
IUGR = intrauterine growth retardation 
Table 5.
Outcome GUCH pregnancies
Non-CVD 
pregnancies
p 
value*
Singleton pregnancy 26/27 (96.3%) 527/540 (97.6%) 0.50
Male infant gender 14/27 (51.9%) 292/540 (54.1%) 0.82
Pregnancy duration 
(weeks)+
38
(range 36 - 41)
39
(range 22 - 41) 0.14
Premature birth§ 3/27 (11.1%) 22/537 (4.1%) 0.11
Small for gestational 
age§ 5/27 (18.5%) 45/537 (8.4%) 0.08
Birth weight (grams)#
3027 (2821, 
3232)
[3030]
3212 (3168, 
3256)
[3230]
0.045
Congenital 
malformations 2/27 (7.4%) 13/540 (2.4%) 0.06
Still births / neonatal 
deaths 0/27 (0%) 5/540 (1%) 1.00
Comparison of offspring outcomes between pregnancies in the two 
study cohorts 
+ Pregnancy duration is expressed as median followed by range 
in weeks
§ Rates of premature birth and small for gestational age babies 
(<10th centile for gestational age) are expressed as percentages 
out of all live births
# Birth weight is expressed as mean with 95% confidence intervals 
followed by median in square brackets.
* Statistically significant differences are shown in bold
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Limitations
The small Maltese GUCH population and the even smaller 
numbers of female patients that became pregnant during the 
study period, which in themselves are an inevitable consequence 
of the small size of the country, represent the main limitation of 
this study.  It is possible that some women with CHD of mild 
complexity who were not under regular specialist follow-up and 
were deemed to be at very low risk in pregnancy might have 
delivered in private centres and thus failed to be included due 
to lack of documentation in hospital records.  Notwithstanding, 
the fact that most Maltese deliveries on the islands take place 
in state-run hospitals irrespective of maternal or obstetric risk 
makes it likely that missed GUCH pregnancies were few and 
that only women with mild or trivial lesions were selected out. 
A further limitation is the retrospective nature of the study which 
resulted in some patients having incomplete data, though this 
was limited to few patients who were not under regular specialist 
clinical follow-up.  The comparison of outcomes between GUCH 
and non-CVD cohorts relied on outcomes routinely collected 
by NOIS.  Because NOIS only captures pregnancies that end 
in the birth of a baby of ≥22 completed weeks, comparison of 
miscarriage rates could not be performed.
Conclusions
Although pregnancy in the presence of maternal CHD can be 
of higher risk to mother and foetus, our findings reinforce the 
fact that, with careful preconceptual counselling and close 
monitoring by a specialist team of cardiologists, obstetricians 
and anaesthetists, pregnancy outcomes can be comparable to 
those in women without heart disease.  The presence of maternal 
CHD appears to predispose to lower infant birth weight, even in 
women with less complex disease and good baseline functional 
status.  While risk-predicting tools are a helpful guide, advice 
to prospective mothers needs to be tailored to the individual 
patient’s case, taking into account not only the woman’s functional 
status but also the services and infrastructure of the institution 
where the pregnancy will be followed and delivery performed so 
as to ensure safety at all stages.[28]  Finally, large multi-centre 
collaborations like the European Society of Cardiology’s ROPAC 
[29] which also include data about follow-up after pregnancy, will 
help shed more light on the long-term impact that pregnancy 
could have on cardiac function in women with CHD, particularly 
in an era where access to assisted reproductive technology, 
often with use of hormonal therapy and a higher possibility of 
multiple pregnancies, is increasing in many countries. 
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